Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma

Clinical Evaluation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) 100 mg BID Oral Administration in Patients Affected by Primary Open Angle Glaucoma (POAG): a Randomized, Double Blind Study

This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).

Patients, after signing the Informed Consent, will enter into a 1- week screening phase during which the baseline tests will be conducted.

Subjects will be randomized in a 1:1 ratio to the following groups:

• group A of 35 patients treated with pressure lowering drugs and placebo;
• group B of 35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.

Study Overview

• Status: Unknown
• Conditions: Glaucoma, Open-Angle
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: CoQ10- MINIACTIVES

• Study Type: Interventional
• Enrollment (Anticipated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Stanislao Rizzo; Phone Number: +39 06 301 54 929; Email: stanislao.rizzo@policlinicogemelli.it

Study Locations

• Italy
  • Rome, Italy
    • Recruiting
    • U.O. di Oculistica, Fondazione Policlinico Agostino A. Gemelli,
    • Contact: Stanislao Rizzo, MD
  • PI
    • Pisa, PI, Italy, 56124
      • Recruiting
      • UO Oculistica - PO Cisanello
      • Contact: Michele Figus, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 38 years to 78 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Patient Informed consent form (ICF) signed
• M & F Aged ≥ 40 and ≤ 80 years at the time of the signature of ICF
• Patients with Primary Open Angle Glaucoma (POAG) stage early-moderate according to Hodapp-Parrish-Anderson criteria (MD less than -12 dB)
• Patients must be diagnosed with POAG at least 1 year before the screening visit in this study.
• Anamnesis with at least 1 value of Intraocular pressure (IOP) >21mmHg documented any time prior the initiation of the stable treatment with anti-hypertensive topical drugs.
• Patients affected by POAG and under stable treatment with anti-hypertensive topical drugs in the previous 6 months prior to enrolment to maintain IOP ≤18 mmHg.
• Corrected visual acuity (using ETDRS tables) ≥ 8/10
• Transparent dioptric means to allow the examination of the OCT >25 μm.
• Pachymetry values between 500 and 600 μm.
• Patients have to show a stable visual field in the previous 6 months prior to enrolment (where by stable visual field it is intended that the patient must remain within the same stage of POAG severity (i.e. early or moderate) during the previous 6 months before the enrolment).
• Willing to follow all study procedures, including attending all site visits, tests and examinations.
• Women must agree to be using two forms of effective contraception, be post-menopausal from at least 12 months prior to trial entry, or surgically sterile.

Exclusion criteria:

• Patients with a severe defect of POAG according to Hodapp-Parrish-Anderson criteria.
• Previously diagnosed optic neuropathies.
• Diabetic retinopathy or Hypertensive retinopathy.
• Decompensated diabetes.
• Not stabilized hypertension (SAP and/or DAP) despite under adequate pharmacological treatment.
• Retinal pathologies including hereditary forms.
• Neurological, neurodegenerative or cerebrovascular conditions.
• No previous history or presence of any disease involving cornea or retina.
• Patients with a significantly progressive opacity of lens in the previous 3 months prior to enrolment (where by significant progressive opacity of lens it is intended patients who have been diagnosed with cataracts of any aetiology and for whom surgery is being considered).
• No surgical intervention for cataract in the previous 3 months prior to enrolment.
• Eye inflammatory conditions (uveitis) diagnosed any time in the patient's history.
• Treatment with topical or systemic neuroprotective agents different from CoQ10. These patients can be admitted in the study after at least a 1 month of wash-out period.
• Treatment with warfarin.
• Treatment with miotic drugs able to influence the visual field.
• Treatment with systemic or topical steroids.
• Refractive defects beyond the 5 spherical diopters, both positive and negative and over 3 cylindrical.
• Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular, cancer or hematological disease.
• Known drug and/or alcohol abuse.
• Mental incapacity that precludes adequate understanding or cooperation.
• Participation in another investigational study or blood donation within 3 months prior to ICF signature.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: group A; 35 patients treated with pressure lowering drugs and placebo	Dietary supplement: Placebo; Placebo
Experimental: group B; 35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.	Dietary supplement: CoQ10- MINIACTIVES; COQUN oral formulation 100 mg BID

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pattern Electroretinogram Amplitude (PERG P50-N95 A)	To evaluate the difference of mean changes of Pattern Electroretinogram Amplitude (PERG P50-N95 A) (μV) observed between the two study groups.	between the baseline visit (V0) and the last study visit after 12 months of treatment (V3)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pattern Electroretinogram Amplitude (PERG P50-N95 A)	To evaluate the difference of mean changes of Pattern Electroretinogram Amplitude (PERG P50-N95 A) (μV) observed between the two study groups.	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Pattern Electroretinogram Amplitude Implicit Times (PERG P50 IT)	To evaluate the changes from baseline to each study visit between the two study groups in Pattern Electroretinogram Amplitude Implicit Times (PERG P50 IT) in milliseconds (ms)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Visual Evoked Potentials Implicit Times (VEP P100 IT)	To evaluate the changes from baseline to each study visit between the two study groups in Visual Evoked Potentials Implicit Times (VEP P100 IT) in milliseconds (ms)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Visual Evoked Potentials Amplitude (VEP N75-P100 A)	To evaluate the changes from baseline to each study visit between the two study groups in Visual Evoked Potentials Amplitude (VEP N75-P100 A) in microvolt (μV)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Visual field	To evaluate the changes from baseline to each study visit between the two study groups in Visual field (separately MD and PSD) evaluated by Humphrey field analyzer (HFA) Sita Standard 30-2	from baseline to each study visit (V1, V2, V3)
Contrast sensitivity	To evaluate the changes from baseline to each study visit between the two study groups in Contrast sensitivity measured with Vistech tables (Vision Chart from CSO)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)
Optical Coherence Tomography	To evaluate the changes from baseline to each study visit between the two study groups in Peripapillary retinal nerve fiber layer (RNFL) thickness, macular RNFL, macular ganglion cell layer (GCL), macular inner plexiform layer (IPL) assessed with natural pupils by the means of spectral domain Optical Coherence Tomography (OCT, Heidelberg Spectralis)	between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3)

Collaborators and Investigators

• Sponsor: VISUfarma SpA

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2019
• Primary Completion (Anticipated): August 30, 2021
• Study Completion (Anticipated): August 30, 2021

Study Registration Dates

• First Submitted: May 9, 2019
• First Submitted That Met QC Criteria: July 26, 2019
• First Posted (Actual): July 30, 2019

Study Record Updates

• Last Update Posted (Actual): April 28, 2020
• Last Update Submitted That Met QC Criteria: April 24, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Ocular Hypertension; Glaucoma; Glaucoma, Open-Angle; Physiological Effects of Drugs; Micronutrients; Vitamins; Coenzyme Q10
• Other Study ID Numbers: VF-GLAU-CoQ10/2019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No